March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Rock Inhibitor Eye Drops Accelerate Corneal Endothelium Wound Healing In A Primate Model
Author Affiliations & Notes
  • Naoki Okumura
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Noriko Koizumi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Morio Ueno
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Yuji Sakamoto
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Hiroaki Takahashi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Kenta Yamasaki
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Ryuzo Torii
    Research Center for Animal Life Science, Shiga University, Otsu, Japan
  • Junji Hamuro
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships  Naoki Okumura, None; Noriko Koizumi, None; Morio Ueno, None; Yuji Sakamoto, None; Hiroaki Takahashi, None; Kenta Yamasaki, None; Ryuzo Torii, None; Junji Hamuro, None; Shigeru Kinoshita, None
  • Footnotes
    Support  The Adaptable and Seamless Technology Transfer Program through Target-driven R & D (AS2314212G) and Highway Program for realization of regenerative medicine (for Kinoshita)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5999. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naoki Okumura, Noriko Koizumi, Morio Ueno, Yuji Sakamoto, Hiroaki Takahashi, Kenta Yamasaki, Ryuzo Torii, Junji Hamuro, Shigeru Kinoshita; Rock Inhibitor Eye Drops Accelerate Corneal Endothelium Wound Healing In A Primate Model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5999.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We previously reported that Rho kinase (ROCK) inhibitor Y-27632 promotes wound healing of corneal endothelial cells (CECs) in a rabbit model and showed the possibility of the clinical application for humans who are in a corneal endothelial deficient condition (BJO, 2011). The purpose of this present study was to demonstrate the effect of Y-27632 on wound healing in a primate corneal endothelial dysfunction model.

Methods: : As a corneal endothelial partially-injured model, the corneal endothelium of 6 cynomolgus monkeys (3-5 years-of-age; estimated equivalent human age: 15-20 years) was damaged by transcorneal freezing with a 7-mm-diameter probe. Ten mM of Y-27632 was then applied topically in 1 eye of each animal 6 times daily, while phosphate buffered saline was applied in the fellow eye as a control. The corneal appearance of each eye was then examined by slit-lamp microscopy, and in vivo corneal endothelial cells were examined by noncontact specular microscopy. Four weeks after treatment, the phenotype of the reconstructed corneal endothelium was evaluated by scanning electron microscopy and by immunohistochemical analysis of ZO-1 and Na+/K+-ATPase.

Results: : Slit-lamp microscopy revealed that both Y-27632 treated and non-treated corneas became hazy after transcorneal freezing, and then recovered their transparency within 4 weeks. Noncontact specular microscopy revealed that corneal endothelial cell density was significantly higher in the Y-27632 group compared to the controls at 4 weeks (3123.7±82.4 and 1833.0±90.8 cells/mm2, respectively; p<0.01). Although fairly normal appearing same-size hexagonal cells were observed in the Y-27632 treated eyes, a big variation in cell size and poorly formed cell junctions were observed in the controls by electron microscopy. The percentage of ZO-1 and Na+/K+-ATPase positive cells among the regenerated area in the Y-27632 group was significantly higher than in the controls (98.7±1.3 vs 48.7±7.6%; p<0.05, and 100.0±0.0 vs 76.6±2.0%, respectively; p<0.01).

Conclusions: : ROCK inhibitor Y-27632 promotes recovery of corneal endothelial cell density and wound healing in terms of both morphology and function. These findings indicate that ROCK inhibitor eye drops might hold the promise of becoming a new pharmaceutical agent for treating corneal endothelial dysfunction.

Keywords: cornea: endothelium • cornea: basic science • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×